December 1, 2008
By:Eric S. Langer
A closer look at the past year's development in India.
 |
November 1, 2008
By:Eric S. Langer
If Indian biologics manufacturers can establish a track record for recombinant products, enhance quality image, maintain cost competitiveness, and demonstrate technology transfer and regulatory knowhow, they are likely to be in the middle of the next boom in biologics manufacturing.
|
October 1, 2008
By:Abhijeet Kelkar, Eric S. Langer
The rapid growth of the pharmaceutical industry in India is yet to create significant changes in the Indian distribution system.
|
August 1, 2008
By:Eric S. Langer
What the Indian government is doing to make its biotech sector as strong as its IT sector.
|
July 1, 2008
By:Eric S. Langer
The bioinformatics industry is currently one of the fastest growing fields in India's biotechnology sector. Indian IT companies have several advantages in the bioinformation field and can continue to grow their opportunities worldwide.
|
May 1, 2008
By:Eric S. Langer, Faiz Kermani, PhD
Most local and global clinical research organizations (CROs) consider an operational presence in India as key to their overall business plans. India is clearly on course to become the next hub for clinical trials.
|
April 1, 2008
By:Eric S. Langer
Did the 2005 Patents Act engender a Western intellectual property rights culture in the country?
|
March 1, 2008
By:Eric S. Langer
India is restructuring its regulation of biopharmaceuticals to help the country's industry compete internationally.
|
February 1, 2008
By:Eric S. Langer
Indian biogenerics could form a major piece of the global biotherapeutics market in the future.
|
| 
